Higher depression rates and similar cardiovascular comorbidity in psoriatic arthritis compared with rheumatoid arthritis and diabetes mellitus

George E. Fragoulis, Gerasimos Evangelatos, Nikolaos Tentolouris, Kalliopi Fragkiadaki, Stylianos Panopoulos, George Konstantonis, Alexios Iliopoulos, Katerina Chatzidionysiou, Petros P. Sfikakis and Maria G. Tektonidou

Abstract
Background: We explore the spectrum of comorbidities in psoriatic arthritis (PsA) patients in comparison with other high comorbidity-burden diseases like rheumatoid arthritis (RA) and diabetes mellitus (DM).
Methods: Two hundred and fifteen PsA patients, cross-sectionally collected from two tertiary hospitals, were compared with 215 RA and 215 DM patients (age/sex-matched, similar disease duration). Cardiovascular risk factors [hypertension, current smoking, hyperlipidaemia, obesity (body mass index [BMI] ≥30)], coronary artery disease (CAD), stroke, major adverse cardiac events (MACEs; combined CAD and stroke), depression, osteoporosis and malignancies were recorded. Odds ratios (ORs) for stroke, CAD and MACE were adjusted for age, sex, hypertension, smoking, hyperlipidaemia, BMI, glucocorticoids use and those for depression were adjusted for age, sex, disease duration, skin involvement and smoking. Within the PsA group, associations between comorbidities and demographic/clinical features were assessed.
Results: Depression [OR (95% confidence interval [CI]): 3.02 (1.57–5.81)], obesity [OR (95% CI): 2.83, (1.65–4.86)] and hyperlipidaemia [OR (95% CI): 1.96 (1.32–2.90)] were more prevalent in PsA compared with RA, while no differences were observed for CAD, stroke, MACE and malignancies. Depression [OR (95% CI): 4.85 (2.37–9.93)] and osteoporosis [OR (95% CI): 6.22 (1.33–29.2)] were more common in PsA than in DM. Hypertension, but not the other cardiovascular risk factors, was more frequent in DM [OR (95% CI) 0.49 (0.33–0.74)]. However, prevalence of stroke, CAD and MACE did not differ between PsA and DM. Within PsA group, depression was associated with age [OR (95% CI): 1.03 (0.99–1.06)], female sex [OR (95% CI): 3.47 (1.51–7.99)] and smoking [OR (95% CI): 2.78 (1.31–5.88)] while MACEs were associated with age [OR (95% CI): 1.08 (1.00–1.17)], male sex [OR (95% CI) for females: 0.26 (0.06–1.23) and hypertension [OR (95% CI): 6.07 (1.12–33.0)]. No differences were recorded in comorbidities between the different PsA phenotypes.
Conclusion: Depression was more prevalent in PsA compared with RA and DM, while cardiovascular comorbidity was comparable to both groups, supporting the need for their assessment and management.

Keywords: cardiovascular disease, comorbidities, depression, diabetes mellitus, psoriatic arthritis, rheumatoid arthritis

Received: 27 July 2020; revised manuscript accepted: 5 November 2020.
**Introduction**

Psoriatic arthritis (PsA) is an inflammatory arthritis affecting around 0.8% of the general population. It is characterized by skin involvement, arthritis, spondylitis, enthesitis, as well as manifestations from other tissues-organs. Emerging data have shown that traditional cardiovascular risk factors such as obesity and cardiovascular events, as well as mental-health disorders, are more prevalent in PsA compared with healthy individuals while the prevalence of other comorbidities such as osteoporosis is comparable to that observed in the general population. Accumulating evidence has shown that comorbidities in PsA have a significant impact on health-related quality of life and clinical outcomes. However, only a few of the studies assessing comorbidities in PsA have examined a wide spectrum of them or made a direct comparison with other rheumatic inflammatory disorders such as rheumatoid arthritis (RA). It is increasingly recognized that the latter is accompanied by several comorbidities including cardiovascular disease. Compared with PsA, some studies have shown only minor differences in the number and type of comorbidities, while others have found that PsA patients have higher frequency of specific comorbidities such as hypertension, hyperlipidaemia, diabetes, ischaemic heart disease and depression. Specifically for depression, results so far are conflicting. A direct comparison with a chronic disorder of high comorbidity burden such as diabetes mellitus (DM) has not been performed hitherto.

We sought to investigate in a cross-sectional study the prevalence of major comorbidities in patients with PsA in comparison with RA and DM. Furthermore, we assessed whether comorbidities differ between the various PsA phenotypes (e.g. axial disease) and any potential associations between comorbidities and patients’ clinical characteristics.

**Materials and methods**

**Patient population and study design**

Data were recorded from PsA patients meeting the CASPAR criteria, who visited the outpatients’ rheumatology clinics from two different tertiary referral hospitals between December 2018 and June 2019. Patients needed to have a follow-up of at least 6 months to be included in the analysis. RA patients meeting the ACR-EULAR 2010 criteria and DM patients of type 1 and 2 followed in the diabetes outpatient clinic of our department, both age- and sex-matched (matching 1:1:1) and of similar disease duration with PsA patients, were used as control groups. PsA and RA patients with concomitant DM were excluded.

Recorded features included the following: epidemiological characteristics [age, sex, weight, height, body mass index (BMI), disease duration], ever-present enthesitis, dactylitis, involvement of distal interphalangeal joints (DIP), spine, nails, eyes and bowel, as well as laboratory features (rheumatoid factor and anti-CCP status, erythrocyte sedimentation rate, C-reactive protein), medications, clinical features [number of tender and swollen joint counts, body surface area (BSA) of skin involvement] and comorbidities: traditional cardiovascular risk factors (hypertension, hyperlipidaemia, obesity, current smoking), cardiovascular events (history of myocardial infarction/angina, stroke), osteoporosis, depression and history of malignancies, at the time of inclusion in the study. The following definitions were used: PsA-oligoarthritis pattern: <5 joints involved at disease diagnosis; PsA-RA-like pattern: >4 joints at disease diagnosis; usually symmetrical, axial disease: radiologic findings of sacroiliac joints or spine involvement, hypertension: blood pressure >140 mmHg over 90 mmHg in two measurements or when antihypertensive treatment was administered; hyperlipidaemia: cholesterol >200 mg/dl and/or low-density lipoprotein >130 mg/dl and/or triglycerides >150 mg/dl and/or receiving lipid-lowering therapy; obesity: BMI ≥30; DM: use of anti-diabetic drugs, coronary artery disease (CAD): myocardial infarction or angina; major adverse cardiac event (MACE): CAD, stroke or death; osteoporosis: bone density <2.5 or less in dual-energy X-ray absorptiometry or requirement for anti-osteoporotic treatment; depression: treatment with antidepressants prescribed by a psychiatrist. Disease duration was defined as the time between disease diagnosis of PsA and time of enrolment to the study.

Prevalence of comorbidities was compared between PsA, RA and DM patients, after adjustment for certain variables (see Results section). Further analyses were performed within the PsA group to identify possible associations between clinically meaningful comorbidities and epidemiological characteristics. Comparison of the comorbidites was also performed between the two major phenotypes of PsA, namely “RA-like” and “oligoarthritis” pattern as well as between PsA patients with or without axial involvement. The number of patients exhibiting only axial disease would be included.
or DIP involvement was not sufficient for separate analyses for these subgroups.

The study was approved by the ethical boards of the participating hospitals (“Laiko” ethics committee; approval number: 967-19, and “NIMTS” ethics committee; approval number: 80-19). Written informed consent was obtained from all patients.

Statistics
Two-sided Fisher’s and Mann–Whitney tests were used to compare categorical and numerical characteristics, respectively. Binomial logistic regression was performed, both univariate and multivariate, having as dependent variables the examined comorbidities and correcting for relevant confounders. Results were expressed as odds ratios (ORs). Statistical significance is considered for p-values less than 0.05 and 0.1 in univariate and multivariate analyses, respectively. GraphPad Prism 5.00 (GraphPad Software, Inc., USA) and SPSS 24.0 (SPSS software, USA) were used.

Results
Two hundred and fifteen PsA patients were included and compared with 215 RA patients and 215 DM patients (90 with DM type 1, 125 with DM type 2). Groups were age- and sex-matched (1:1:1) and had similar disease duration (Table 1). Clinical and laboratory characteristics as well as information about the treatment of PsA and RA patients are shown in Table 2.

Comparison of epidemiological characteristics and comorbidities between PsA and RA patients
Patients with PsA had higher weight, height and BMI compared with RA patients (Table 1). Hyperlipidaemia, obesity and depression were also more frequent in PsA versus RA patients while current smoking was similar between the two groups. Depression remained more prevalent than RA after adjusting for age, sex, disease duration and smoking (Table 3). No differences were observed between PsA and RA in the frequency of malignancies (adjusted for age and disease duration), osteoporosis (adjusted for glucocorticoids treatment), hypertension, or CAD, stroke and MACE. For MACE, CAD and stroke, adjustments were made for age, sex, smoking, hypertension, hyperlipidaemia, BMI and glucocorticoids use (Table 3). The number of comorbidities was significantly higher in PsA compared with RA patients [median (range); 1 (0–4) versus 0 (0–4), p = 0.003, respectively].

Comparison of epidemiological characteristics and comorbidities between PsA and DM patients
Patients with PsA were taller than those with DM but had comparable weight and BMI (Table 1). The prevalence of hyperlipidaemia,
Table 2. Clinical, laboratory and treatment characteristics of the PsA and RA patients included in the study.

| Characteristic                        | PsA  
|                                      | $n=215$ | RA  
|                                      |         | $n=215$ |
|--------------------------------------|---------|---------|
| **Type of arthritis at diagnosis**   |         |         |
| Oligoarthritis$, n [\%]              | 76 (35.4) |         |
| RA-like, n [\%]                      | 122 (56.7) | N/A |
| Axial$^b$ only, n [\%]               | 14 (6.5) |         |
| DIP only, n [\%]                     | 3 (1.4) |         |
| Tender joints count, mean $\pm$ SD$^c$ | 1.8 $\pm$ 2.9 | 1.8 $\pm$ 3.4 |
| Swollen joints count, mean $\pm$ SD$^c$ | 1.1 $\pm$ 2.3 | 1.4 $\pm$ 2.9 |
| **Other features**                   |         |         |
| Body surface area$^c$, mild/moderate/severe$^d$, n [\%] | 174 (80.9)/39 (18.1)/2 (0.9) |         |
| Axial involvement$^b$, n [\%]        | 73 (33.9) |         |
| DIP involvement, n [\%]              | 13 (6.0) |         |
| Dactylitis, n [\%]                   | 42 (19.5) | NA |
| Enthesitis, n [\%]                   | 47 (21.9) |         |
| Nail involvement, n [\%]             | 68 (31.6) |         |
| Eye manifestations, n [\%]           | 6 (2.8) |         |
| Bowel manifestations, n [\%]         | 11 (5.1) |         |
| **Laboratory features**              |         |         |
| ESR, mm/h; mean (SD)$^c$              | 22.0 (18.9) | 22.8 (21.4) |
| CRP, mg/l; mean (SD)$^c$              | 4.1 (3.9) | 11.4 (4.9) |
| Positive RF, n [\%]                  | N/A | 111/207 (53.6) |
| Anti-CCPs, n [\%]                    | N/A | 80/155 (51.6) |
| **Treatment$^e$**                     |         |         |
| Methotrexate, n [\%]                 | 112 (52.1) | 138 (64.2) |
| Sulfasalazine, n [\%]                | 6 (2.8) | 2 (0.9) |
| Cyclosporine, n [\%]                 | 13 (6.0) | 1 (0.4) |
| Leflunomide, n [\%]                  | 19 (8.8) | 23 (10.7) |
| Hydroxychloroquine, n [\%]           | 1 (0.5) | 41 (19.1) |
| Anti-TNF, n [\%]                     | 39 (18.1) | 55 (25.6) |
| Anti-CD20, n [\%]                    | 0 (0.0) | 6 (2.8) |
| Anti-IL6R, n [\%]                    | 0 (0.0) | 23 (10.7) |

(Continued)
Comorbidities within PsA group

In PsA patients, univariate analyses showed that depression, which was observed in 19.5% of PsA patients, was associated with age, female sex and current smoking (Table 4). These associations remained significant in multivariable analysis after adjustments for factors that displayed statistically significant difference in the univariate analyses or were clinically meaningful, namely age, sex, smoking, disease duration, and skin involvement as assessed by BSA (Table 4).

MACEs were significantly associated with age, male sex, hypertension and hyperlipidaemia. After adjusting for these factors as well as for other relevant co-variates, including smoking and BMI, age, hypertension and male sex remained significant (Table 4). Numerical values for the features examined are presented in Supplemental material Table 1 online.

No differences in patient characteristics or in the prevalence of comorbidities were found between “RA-like” and “oligoarthritis” patterns of PsA (Supplemental Table 2) or in patients who had axial involvement compared with those without (Supplemental Table 3).

Discussion

Comorbidities such as cardiovascular disease, metabolic syndrome and depression constitute an important aspect of PsA. As captured in the recently published EULAR recommendations, they should be taken into account in the

---

**Table 2.** (Continued)

| Characteristic | PsA n=215 | RA n=215 |
|---------------|-----------|-----------|
| Abatacept, n (%) | 2 (0.9) | 12 (5.6) |
| Anti-IL-17, n (%) | 15 (7.0) | 0 (0.0) |
| Anti-IL-23/-12, n (%) | 10 (4.7) | 0 (0.0) |
| Apremilast, n (%) | 13 (6.1) | 0 (0.0) |
| Current use of glucocorticoids*, n (%) | 53 (24.7) | 152 (70.7) |
| Past use of glucocorticoids, n (%) | 61 (28.4) | 53 (24.7) |
| Past use of cDMARDs, number; median (IQR) | 1 [1–1] | 1 [1–2] |
| Past use of bDMARDs, number; median (IQR) | 1 [1–2] | 2 [1–3] |

*Arthritis in ≤4 joints.
†Defined as presence of radiological findings [sacroilitis or spondylitis/syndesmophytes] in X-rays or magnetic resonance imaging.
‡At the time of inclusion to the study.
¶Mild: <3% body surface area (BSA); moderate: 3–10% BSA; severe: >10% BSA.
∥Treatment received at the time of inclusion to the study.
*Mean ± SD dose was 3.6 ± 1.3 mg/day prednisolone or equivalent.
bDMARD, biologic disease modifying anti-rheumatic drug; CCP, cyclic citrullinated peptide; cDMARD, conventional disease modifying anti-rheumatic drug; CRP, C-reactive protein; DIP, distal interphalangeal; ESR, erythrocyte sedimentation rate; IL, interleukin; IL6R, interleukin 6 receptor; IQR, interquartile range; mm/h, millimetres per hour; n, number; PsA, psoriatic arthritis; RA, rheumatoid arthritis; RF, rheumatoid factor; TNF, tumour necrosis factor.
Table 3. Comparison of comorbidities between psoriatic arthritis, rheumatoid arthritis and diabetes mellitus patients.

| Comorbidity       | PsA n = 215 | RA n = 215 | DM n = 215 | PsA versus RA | PsA versus DM |
|-------------------|-------------|------------|------------|---------------|---------------|
|                   |             | Crude OR (95% CI) | Adjusted OR (95% CI) | Crude OR (95% CI) | Adjusted OR (95% CI) |
| Smoking           | 76 (35.4)   | 1.35 (0.90–2.03) | 0.84 (0.57–1.24) |
| Hyperlipidaemia   | 101 (47.0)  | 1.96 (1.32–2.90) | – | – |
| Hypertension      | 62 (28.8)   | 1.30 (0.84–1.99) | – | – |
| Obesity           | 50 (29.4)   | 2.83 (1.65–4.86) | 0.72 (0.47–1.10) |
| Coronary disease  | 10 (4.7)    | 1 (0.41–2.45) | 1.05 (0.31–3.57) | 0.61 (0.27–1.37) | 0.66 (0.23–1.91) |
| Stroke            | 8 (3.7)     | 4.12 (0.86–19.6) | 5.06 (0.80–32.1) | 1.15 (0.41–3.22) | 1.20 (0.35–4.12) |
| MACEs             | 12 (5.6)    | 1 (0.44–2.28) | 1.20 (0.40–3.63) | 0.52 (0.25–1.08) | 0.42 (0.16–1.10) |
| Osteoporosis      | 12 (5.6)    | 0.46 (0.21–1.03) | 0.67 (0.28–1.64) | 6.22 (1.33–29.2) | – |
| Depression        | 42 (19.5)   | 3.24 (1.74–6.04) | 3.02 (1.57–5.81) | 4.11 (2.10–8.05) | 4.85 (2.37–9.93) |
| Malignancy        | 12 (5.6)    | 1.76 (0.68–4.55) | 1.60 (0.60–4.26) | – | – |

- Adjusted for age, sex, smoking, hypertension, hyperlipidaemia, body mass index, glucocorticoids use.
- Adjusted for glucocorticoids treatment; none of the DM patients was receiving steroids.
- 6/42 (14.3%) PsA patients were already on antidepressants [mean ± SD time: 16.8 ± 10.9 months] at the time of PsA diagnosis [in five out of six, anti-depressants started after the diagnosis of psoriasis]. The respective figure for RA was 2/15 (13.3%).
- Adjusted for age, sex, disease duration, smoking.
- Adjusted for age, disease duration.

CI, confidence interval; DM, diabetes mellitus; MACE, major adverse cardiovascular event; OR, odds ratio; PsA, psoriatic arthritis; RA, rheumatoid arthritis.
In this study, we examined the prevalence of multiple major comorbidities in a well-characterized PsA cohort and we made comparisons with 1:1 age- and sex-matched RA patients and DM patients.

Depression in PsA is an often neglected comorbidity among patients with PsA, with a high impact on patient quality of life. In our study, depression was present in about 20% of PsA patients, which is comparable to other studies and three recently published meta-analyses in which pooled prevalence of depression in PsA was between 15% and 20%. It has to be highlighted though that there is a wide variation in the reported prevalence of depression across different studies (ranging from 5% to 51%), possibly reflecting different methodologies and tools used for assessment of depression. Interestingly, we also found a higher prevalence of depression in patients with PsA compared with RA or DM. To the best of our knowledge, only a few studies have compared depression prevalence in PsA with RA or DM.

| Table 4. Associations of depression and major adverse cardiovascular events with epidemiological characteristics, within the psoriatic arthritis group. |
| --- |
| **Factors** | **Depression** | **Adjusted OR**
| | Crude OR | p-value | OR (95% CI) | p-value |
| --- | --- | --- | --- | --- |
| Age | 1.029 (1.003–1.056) | 0.029 | 1.03 (0.99–1.06) | 0.05 |
| Sex, female | 2.88 (1.34–6.23) | 0.007 | 3.47 (1.51–7.99) | 0.04 |
| BMI | 1.034 (0.97–1.10) | 0.310 | – | – |
| Obesity | 2.02 (0.94–4.35) | 0.072 | – | – |
| Smoking | 2.74 (1.38–5.46) | 0.004 | 2.78 (1.31–5.88) | 0.008 |
| Disease duration | 1.003 (0.99–1.01) | 0.080 | – | – |
| BSA, mild versus moderate/severe | 0.99 (0.42–2.36) | 0.997 | – | – |
| **Factors** | **MACEs** | **Adjusted OR**
| | Crude OR | p-value | OR (95% CI) | p-value |
| --- | --- | --- | --- | --- |
| Age | 1.10 (1.04–1.17) | 0.001 | 1.08 (1.00–1.17) | 0.042 |
| Sex, female | 0.23 (0.06–0.87) | 0.031 | 0.26 (0.06–1.23) | 0.090 |
| BMI | 1.05 (0.95–1.15) | 0.337 | – | – |
| Obesity | 0.79 (0.20–3.04) | 0.728 | – | – |
| Smoking | 1.33 (0.41–4.34) | 0.638 | – | – |
| Disease duration | 1.002 (0.99–1.01) | 0.846 | – | – |
| Hypertension | 14.5 (3.0–68.4) | 0.001 | 5.12 (0.96–27.4) | 0.056 |
| Hyperlipidaemia | 6.15 (1.32–28.8) | 0.021 | – | – |
| Glucocorticoids | 1.05 (0.27–4.02) | 0.946 | – | – |

Statistically significant values are marked with bold numbers.

+Adjusted for age, sex, smoking, disease duration, body surface area (BSA) (categorized as mild versus moderate/severe).
+Mild: <3% BSA, moderate: 3–10% BSA, severe: >10% BSA.
++Adjusted for age, sex, smoking, hypertension, hyperlipidaemia, BMI, use of glucocorticoids.
BMI, body mass index; CI, confidence interval; MACE: major adverse cardiovascular event; OR: odds ratio.
couple of studies so far, have directly compared the prevalence of depression between PsA and RA. In concert with our findings, Sinnathurai et al.,15 examining data from 490 PsA and 3609 RA patients, found that the former had greater odds for depression [OR (95% confidence interval): 2.1 (1.7–2.6)]. In contrast, Kotsis et al. reported a similar percentage of depression between PsA and RA [21.7% (36.7% in PsA patients with polyarthritis) and 25.1% respectively].16 This difference might be related to the smaller number of PsA patients (n = 83) included in the above study and to the different definitions used for depression. The frequency of depression in RA in our cohort (7.0%) is comparable to that observed in a recent study with the same ethnic background and the same definition for depression.28 The association between female sex and depression in patients with PsA is in agreement with other studies,12,29,30 while current smoking has been previously associated with higher anxiety levels but not depression.20

Furthermore, we found a similar prevalence of cardiovascular events in PsA compared with RA, in agreement with other investigators.2,4,14,31,32 The risk factors for cardiovascular events in PsA remain to be further studied, although it seems that the phenomenon is multifactorial.33 It is also possible that the mechanisms driving the increased cardiovascular risk are slightly different between RA and PsA, with the metabolic component being more pronounced in the latter.34 Apart from the inflammatory burden of PsA,35,36 traditional risk factors such as hypertension, hyperlipidaemia, DM and obesity contribute.2,34,37 In accordance with other studies, we showed that obesity and hyperlipidaemia were more frequent in PsA compared with RA.38-41 In contrast, PsA patients in our cohort did not differ from individuals with DM in terms of weight and BMI. Additionally, although patients with DM displayed a higher prevalence of hypertension, the two groups had similar prevalence of hyperlipidaemia, stroke, CAD and MACE, highlighting that cardiovascular burden in PsA is comparable to that observed in DM, a chronic metabolic disorder which is considered as cardiovascular-risk equivalent. It should be acknowledged, however, that the numbers of cardiovascular events in our study were relatively small. Therefore, the strength of these findings should be interpreted with caution. Larger studies are needed to corroborate our findings. Furthermore, our study includes both patients with DM type 1 and with type 2. Although there were differences between these two groups, the prevalence of CAD stroke, and MACE after adjustment for age/gender and BMI was comparable between patients with DM type 1 and those with DM type 2 (data not shown).

In addition, no differences were recorded in the prevalence of malignancies between PsA and RA, in agreement with other studies which enrolled a larger number of patients.42 Of note, no differences were observed in the frequency of comorbidities between the different phenotypes of PsA. Finally, the height difference between PsA and RA or DM in our study warrants further confirmation. The clinical significance of a mean 3 cm height difference, if any, is unclear. One could speculate that this finding could be construed in light of the theory that implicates the biomechanical stress and the “synovio–entheseal” complex in the pathogenesis of PsA.43 In this context, weight difference observed between PsA and RA in our study might be also relevant. Besides, weight and BMI have been recognized as risk factors for PsA development and are associated with adverse treatment outcomes in these patients.39

The strengths of our study include the assessment of a wide range of comorbidities in patients with PsA and the comparison with two age- and sex-matched groups of high comorbidity burden such as patients with RA and, for the first-time, patients with DM after adjustment for multiple potential confounders. In addition, we assessed for the first time whether there were any differences in the prevalence of comorbidities among various PsA phenotypes. We acknowledge that our study has certain limitations. First, this was a cross-sectional study and patients were not screened actively for comorbidities. However, these were longitudinally recorded in patients’ medical files as part of their medical follow-up. To be mentioned, patients with a follow-up of less than 6 months were excluded. Second, some of the examined comorbidities were defined by the received treatment (e.g. anti-depressants prescribed by a psychiatrist), which makes difficult the comparison with other studies using questionnaires or self-reported outcomes. Third, due to lack of data we did not include socio-economic factors such as unemployment in our model.15,20 For the same reason, we did not use a formal comorbidities index such as patients with RA and, for the first-time, patients with DM after adjustment for multiple potential confounders. In addition, we assessed for the first time whether there were any differences in the prevalence of comorbidities among various PsA phenotypes. We acknowledge that our study has certain limitations. First, this was a cross-sectional study and patients were not screened actively for comorbidities. However, these were longitudinally recorded in patients’ medical files as part of their medical follow-up. To be mentioned, patients with a follow-up of less than 6 months were excluded. Second, some of the examined comorbidities were defined by the received treatment (e.g. anti-depressants prescribed by a psychiatrist), which makes difficult the comparison with other studies using questionnaires or self-reported outcomes. Third, due to lack of data we did not include socio-economic factors such as unemployment in our model.15,20 For the same reason, we did not use a formal comorbidities index such.
as Charlson comorbidity index. Instead, we calculated the number of comorbid conditions as has been done in other studies.

In summary, our results support that PsA patients have comparable cardiovascular comorbidities and higher frequency of depression compared with RA and DM. In fact, the risk for depression appears to be 3–5 times higher in PsA versus RA and DM, respectively. Rheumatologists should be aware of the high burden of multiple comorbidities in PsA. Assessment of these comorbidities and a strict management of modifiable risk factors outlined in the current and previous studies is warranted to optimize outcomes for these patients.

Conflict of interest statement
George E Fragoulis: has received speaker honoraria from Janssen, travelling grants from AbbVie and MSD.

Gerasimos Evangelatos: does not have conflicts of interest related to this work.

Nikolaos Tentolouris: does not have conflicts of interest related to this work.

Kalliopi G Fragkiadaki: does not have conflicts of interest related to this work.

Stylianos Panopoulos: does not have conflicts of interest related to this work.

Alexios Iliopoulos: does not have conflicts of interest related to this work.

Katerina Chatzidionysiou: has received consultant fees from AbbVie, Pfizer, Lilly.

Petros P Sfikakis: has received consultant fees and unrestricted grants from AbbVie, Pfizer, MSD, Roche, UCB, GSK, Novartis deposited to the Special Account for Research Funding (ELKE) of the National and Kapodistrian University of Athens Medical School.

Maria G Tektonidou: has received consultant fees and unrestricted grants from AbbVie, GSK, Genesis, MSD, Novartis, Pfizer and UCB deposited to the Special Account for Research Funding (ELKE) of the National and Kapodistrian University of Athens Medical School.

Funding
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

ORCID iDs
George E Fragoulis https://orcid.org/0000-0003-4932-7023
Maria G. Tektonidou https://orcid.org/0000-0003-2238-0975

Supplemental material
Supplemental material for this article is available online.

References
1. Alinaghi F, Calov M, Kristensen LE, et al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol 2019; 80: 251–265.e219.

2. Jamnitski A, Visman IM, Peters MJ, et al. Prevalence of cardiovascular diseases in psoriatic arthritis resembles that of rheumatoid arthritis. Ann Rheum Dis 2011; 70: 875–876.

3. Han C, Robinson DW Jr, Hackett MV, et al. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 2006; 33: 2167–2172.

4. Nas K, Karkucak M, Durmus B, et al. Comorbidities in patients with psoriatic arthritis: a comparison with rheumatoid arthritis and psoriasis. Int J Rheum Dis 2015; 18: 873–879.

5. Kamalaraj N, El-Haddad C, Hay P, et al. Systematic review of depression and anxiety in psoriatic arthritis. Int J Rheum Dis 2019; 22: 967–973.

6. Zhao SS, Miller N, Harrison N, et al. Systematic review of mental health comorbidities in psoriatic arthritis. Clin Rheumatol 2020; 39: 217–225.

7. Zusman EZ, Howren AM, Park JYE, et al. Epidemiology of depression and anxiety in patients with psoriatic arthritis: a systematic review and meta-analysis. Semin Arthritis Rheum. Epub ahead of print 13 February 2020. DOI: 10.1016/j.semarthrit.2020.02.001.

8. Gulati AM, Michelsen B, Diamantopoulos A, et al. Osteoporosis in psoriatic arthritis: a cross-sectional study of an outpatient clinic population. RMD Open 2018; 4: e000631.

9. Perez-Chada LM and Merola JF. Comorbidities associated with psoriatic arthritis: review and update. Clin Immunol 2020; 214: 108397.
10. Husni ME, Merola JF and Davin S. The psychosocial burden of psoriatic arthritis. Semin Arthritis Rheum 2017; 47: 351–360.

11. Haugeberg G, Michelsen B and Kavanaugh A. Impact of skin, musculoskeletal and psychosocial aspects on quality of life in psoriatic arthritis patients: a cross-sectional study of outpatient clinic patients in the biologic treatment era. RMD Open 2020; 6: e001223.

12. Michelsen B, Kristianslund EK, Sexton J, et al. Do depression and anxiety reduce the likelihood of remission in rheumatoid arthritis and psoriatic arthritis? Data from the prospective multicentre NOR-DMARD study. Ann Rheum Dis 2017; 76: 1906–1910.

13. Ogdie A, Schwartzman S and Husni ME. Recognizing and managing comorbidities in psoriatic arthritis. Curr Opin Rheumatol 2015; 27: 118–126.

14. Shah K, Paris M, Mellars L, et al. Real-world burden of comorbidities in US patients with psoriatic arthritis. RMD Open 2017; 3: e000588.

15. Sinnathurai P, Buchbinder R, Hill C, et al. Comorbidity in psoriatic arthritis and rheumatoid arthritis. Intern Med J 2018; 48: 1360–1368.

16. Kotsis K, Voulgari PV, Tsifetaki N, et al. Anxiety and depressive symptoms and illness perceptions in psoriatic arthritis and associations with physical health-related quality of life. Arthritis Care Res (Hoboken) 2012; 64: 1593–1601.

17. Nikiphorou E, Nurmohamed MT and Szekanecz Z. Editorial: comorbidity burden in rheumatic diseases. Front Med (Lausanne) 2018; 5: 197.

18. Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis 2020; 79: 700–712.

19. Husted JA, Thavaneswaran A, Chandran V, et al. Incremental effects of comorbidity on quality of life in patients with psoriatic arthritis. J Rheumatol 2013; 40: 1349–1356.

20. McDonough E, Ayearst R, Eder L, et al. Depression and anxiety in psoriatic disease: prevalence and associated factors. J Rheumatol 2014; 41: 887–896.

21. Freire M, Rodriguez J, Moller I, et al. Prevalence of symptoms of anxiety and depression in patients with psoriatic arthritis attending rheumatology clinics. Rheumatol Clin 2011; 7: 20–26. 2011/07/29.

22. Meesters JJ, Peterssson IF, Bergman S, et al. Sociodemographic and disease-related factors are associated with patient-reported anxiety and depression in spondyloarthritis patients in the Swedish SpAScania cohort. Clin Rheumatol 2014; 33: 1649–1656.

23. Ballegra C, Hoigaard P, Dreyer L, et al. Impact of comorbidities on tumor necrosis factor inhibitor therapy in psoriatic arthritis: a population-based cohort study. Arthritis Care Res (Hoboken) 2018; 70: 592–599.

24. Cauli A, Gladman DD, Mathieu A, et al. Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study. J Rheumatol 2011; 38: 898–903.

25. Khraishi M, Aslanov R, Rampakakis E, et al. Prevalence of cardiovascular risk factors in patients with psoriatic arthritis. Clin Rheumatol 2014; 33: 1495–1500.

26. Papp K, Poulin Y, Vieira A, et al. Disease characteristics in patients with and without psoriatic arthritis treated with etanercept. J Eur Acad Dermatol Venereol 2014; 28: 581–589.

27. Howells L, Chisholm A, Cotterill S, et al. Impact of disease severity, illness beliefs, and coping strategies on outcomes in psoriatic arthritis. Arthritis Care Res (Hoboken) 2018; 70: 295–302.

28. Panopoulos S, Tektonidou M, Drosos AA, et al. Prevalence of comorbidities in systemic sclerosis versus rheumatoid arthritis: a comparative, multicenter, matched-cohort study. Arthritis Res Ther 2018; 20: 267.

29. Hoigaard P, Ballegra C, Cordtz R, et al. Gender differences in biologic treatment outcomes—a study of 1750 patients with psoriatic arthritis using Danish Health Care Registers. Rheumatology (Oxford) 2018; 57: 1651–1660.

30. Haque N, Lories RJ and de Vlam K. Comorbidities associated with psoriatic arthritis compared with non-psoriatic spondyloarthritides: a cross-sectional study. J Rheumatol 2016; 43: 376–382.

31. Husni ME. Comorbidities in psoriatic arthritis. Rheum Dis Clin North Am 2015; 41: 677–698.

32. Lauper K, Courvoisier DS, Chevallier P, et al. Incidence and prevalence of major adverse cardiovascular events in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. Arthritis Care Res (Hoboken) 2018; 70: 1756–1763.

33. Mathieu S, Motreff P and Soubrier M. Spondyloarthropathies: an independent cardiovascular risk factor? Joint Bone Spine 2010; 77: 542–545.

34. Ferguson LD, Siebert S, McNnes IB, et al. Cardiometabolic comorbidities in RA and PsA:...
lessons learned and future directions. Nat Rev Rheumatol 2019; 15: 461–474.

35. Jamnitski A, Symmons D, Peters MJ, et al. Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Ann Rheum Dis 2013; 72: 211–216.

36. Shen J, Wong KT, Cheng IT, et al. Increased prevalence of coronary plaque in patients with psoriatic arthritis without prior diagnosis of coronary artery disease. Ann Rheum Dis 2017; 76: 1237–1244.

37. Barbarroja N, Arias-de la Rosa I, Lopez-Medina C, et al. Cardiovascular risk factors in psoriatic disease: psoriasis versus psoriatic arthritis. Ther Adv Musculoskelet Dis 2019; 11: 1759720X19880742.

38. Bhole VM, Choi HK, Burns LC, et al. Differences in body mass index among individuals with PsA, psoriasis, RA and the general population. Rheumatology (Oxford) 2012; 51: 552–556.

39. Nikipherou E and Fragoulis GE. Inflammation, obesity and rheumatic disease: common mechanistic links. A narrative review. Ther Adv Musculoskelet Dis 2018; 10: 157–167.

40. Labitigan M, Bahce-Altuntas A, Kremer JM, et al. Higher rates and clustering of abnormal lipids, obesity, and diabetes mellitus in psoriatic arthritis compared with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2014; 66: 600–607.

41. Ozkul O, Yazici A, Akturk AS, et al. Are there any differences among psoriasis, psoriatic arthritis and rheumatoid arthritis in terms of metabolic syndrome and cardiovascular risk factors? Eur J Rheumatol 2019; 6: 174–178.

42. Gross RL, Schwartzman-Morris JS, Krathen M, et al. A comparison of the malignancy incidence among patients with psoriatic arthritis and patients with rheumatoid arthritis in a large US cohort. Arthritis Rheumatol 2014; 66: 1472–1481.

43. McGonagle D, Lories RJ, Tan AL, et al. The concept of a “synovio-entheseal complex” and its implications for understanding joint inflammation and damage in psoriatic arthritis and beyond. Arthritis Rheum 2007; 56: 2482–2491.

44. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373–383.

45. Baviere W, Deprez X, Houvenagel E, et al. Association between comorbidities and quality of life in psoriatic arthritis: results from a multicentric cross-sectional study. J Rheumatol 2020; 47: 369–376.

46. Molto A and Dougados M. Comorbidities in spondyloarthritis including psoriatic arthritis. Best Pract Res Clin Rheumatol 2018; 32: 390–400.